Aging Cell is an open access geroscience journal addressing the biology of aging, from molecular mechanisms of aging to age-related disease.
A team of researchers at the University of Massachusetts Amherst has developed the first dual-color optoelectronic neural probe.
Unlike previous, single probes, which often control brain activity in only one direction—excitation or inhibition, but not both—this new design can enhance and silence the electrical activities of the same neurons within specific cortical layers of the brain. It promises aid the investigation of tightly packed neural microcircuits within the cortex and deep brain regions and, in the longer term, add to the functional mapping of the brain.
Guangyu Xu, assistant associate professor of electrical and computer engineering, an appointee of the Dev and Linda Gupta Professorship at UMass Amherst, and principal investigator of the study hopes the device can ultimately help researchers identify the origin of brain diseases.
A review discusses the current perception of brain immunity and its implications for brain aging, diseases, and immune-based therapies.
The ban on selling Apple Watches with blood-oxygen sensors also impacts the repairs of any Apple Watch with the same feature.
The Human Genome Project promised medical advances from knowledge of the DNA inside nearly every human cell. Now, around 20 years later, nucleic acids — the building blocks of DNA and RNA — are at the centre of powerful approaches to new medicines.
Researchers at the University of Helsinki have uncovered a mechanism that instantaneously generates DNA palindromes, potentially leading to the creation of new microRNA genes from noncoding DNA sequences. This discovery, which was made while studying DNA replication errors and their impact on RNA molecule structures, offers new insights into gene origins.
The complexity of living organisms is encoded within their genes, but where do these genes come from? Researchers at the University of Helsinki resolved outstanding questions around the origin of small regulatory genes, and described a mechanism that creates their DNA palindromes. Under suitable circumstances, these palindromes evolve into microRNA genes.
Genes and proteins: the building blocks of life.
2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first gene-editing CRISPR therapy, Casgevy (or exa-cel), a treatment from CRISPR Therapeutics and partner Vertex for patients with sickle cell disease. This comes on the heels of a similar green light by U.K. regulators in a historic moment for a gene-editing technology whose foundations were laid back in the 1980s, eventually resulting in a 2020 Nobel Prize in Chemistry for pioneering CRISPR scientists Jennifer Doudna and Emmanuelle Charpentier.
That decades-long gap between initial scientific spark, widespread academic recognition, and now the market entry of a potential cure for blood disorders like sickle cell disease that afflict hundreds of thousands of people around the world is telling. If past is prologue, even newer CRISPR gene-editing approaches being studied today have the potential to treat diseases ranging from cancer and muscular dystrophy to heart disease, birth more resilient livestock and plants that can grapple with climate change and new strains of deadly viruses, and even upend the energy industry by tweaking bacterial DNA to create more efficient biofuels in future decades. And novel uses of CRISPR, with assists from other technologies like artificial intelligence, might fuel even more precise, targeted gene-editing—in turn accelerating future discovery with implications for just about any industry that relies on biological material, from medicine to agriculture to energy.
With new CRISPR discoveries guided by AI, specifically, we can expand the toolbox available for gene editing, which is crucial for therapeutic, diagnostic, and research applications… but also a great way to better understand the vast diversity of microbial defense mechanisms, said Feng Zhang, another CRISPR pioneer, molecular biologist, and core member at the Broad Institute of MIT and Harvard in an emailed statement to Fast Company.
7 month treatment, 6 years returned according to a methylation clock, mostly in people who’s biological age was greater than their calendar age.
Dr. Brian Kennedy presents 4 molecules which show promising effects in both healthspan & lifespan in this video. https://pubmed.ncbi.nlm.nih.gov/37289866/http… https://pubmed.ncbi.nlm.nih.gov/37637… https://pubmed.ncbi.nlm.nih.gov/37925… https://pubmed.ncbi.nlm.nih.gov/35584… https://pubmed.ncbi.nlm.nih.gov/35050… https://pubmed.ncbi.nlm.nih.gov/28199… https://pubmed.ncbi.nlm.nih.gov/37904… https://pubmed.ncbi.nlm.nih.gov/37697… https://pubmed.ncbi.nlm.nih.gov/37217… https://pubmed.ncbi.nlm.nih.gov/34952… https://pubmed.ncbi.nlm.nih.gov/34847…
Continue reading “4 MOST Promising Longevity Molecules You NEED To Know” »
This timelapse of future technology begins with 2 Starships, launched to resupply the International Space Station. But how far into the future do you want to go?
Tesla Bots will be sent to work on the Moon, and A.I. chat bots will guide people into dreams that they can control (lucid dreams). And what happens when humanity forms a deeper understanding of dark energy, worm holes, and black holes. What type of new technologies could this advanced knowledge develop? Could SpaceX launch 100 Artificial Intelligence Starships, spread across our Solar System and beyond into Interstellar space, working together to form a cosmic internet, creating the Encyclopedia of the Galaxy. Could Einstein’s equations lead to technologies in teleportation, and laboratory grown black holes.
Continue reading “Timelapse of Future Technology Vol. II (Sci-Fi Documentary)” »
Breast cancer is the most common type of cancer and it is treated with surgical intervention, radiotherapy, chemotherapy, or a combination of these regimens. Despite chemotherapy’s ample use, it has limitations such as bioavailability, adverse side effects, high-dose requirements, low therapeutic indices, multiple drug resistance development, and non-specific targeting. Drug delivery vehicles or carriers, of which nanocarriers are prominent, have been introduced to overcome chemotherapy limitations. Nanocarriers have been preferentially used in breast cancer chemotherapy because of their role in protecting therapeutic agents from degradation, enabling efficient drug concentration in target cells or tissues, overcoming drug resistance, and their relatively small size. However, nanocarriers are affected by physiological barriers, bioavailability of transported drugs, and other factors.
